Nang Kuang Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 02, 2023 at 05:40 pm EDT
Share
Nang Kuang Pharmaceutical Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was TWD 537.06 million compared to TWD 490.83 million a year ago. Net income was TWD 46.62 million compared to TWD 74.6 million a year ago. Basic earnings per share from continuing operations was TWD 0.46 compared to TWD 0.74 a year ago. Diluted earnings per share from continuing operations was TWD 0.46 compared to TWD 0.74 a year ago.
For the nine months, sales was TWD 1,633.92 million compared to TWD 1,339.44 million a year ago. Net income was TWD 233.2 million compared to TWD 190.23 million a year ago. Basic earnings per share from continuing operations was TWD 2.31 compared to TWD 1.88 a year ago. Diluted earnings per share from continuing operations was TWD 2.3 compared to TWD 1.88 a year ago.
NANG KUANG PHARMACEUTICAL CO., LTD. is principally engaged in the manufacture, processing and trading of western medicine. The company main products include injections, sterile injections, powder injections, hard capsules, bare ingots, film ingots, casing ingots, granules and creams, among others. The Company is also engaged in the manufacture, processing and trading of medical equipment. The Company distributes its products within the domestic market and to overseas markets.
NANG KUANG PHARMACEUTICAL CO., LTD. 
